CytoDyn Inc. CYDY Archives - Page 2 of 5

MondayNov 26, 2018 10:31 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Initiate Metastatic Triple Negative Breast Cancer Trial

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its November 23, 2018, receipt of FDA approval for its IND submission, allowing the company to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast cancer (“TNBC”) patients. CytoDyn has identified sites for five clinical trials, and it intends to dose its first several patients with expected initial readout during the first quarter of 2019. “Metastatic triple-negative breast cancer (TNBC) is a deadly disease with poor prognosis due to the spread of the cancer in the blood stream.” CytoDyn Chief Medical Officer Dr. Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., stated…

TuesdayNov 20, 2018 9:49 am

QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 Assigned Leronlimab as Official Name by USAN Council

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) today announced that the United States Adopted Names (“USAN”) Council has designated leronlimab as the official name for its PRO 140. The investigational new drug has not yet been approved for any indication; however, CytoDyn is exploring partnering and licensing agreements for HIV treatment with intention to pursue use of leronlimab in cancer and other autoimmune diseases. “As we recently announced, we are very pleased with the results of our monotherapy higher dose of leronlimab 700 mg showing an impressive responder’s rate of over 90%,” CytoDyn President and Chief Executive Officer Dr. Nader Pourhassan…

MondayNov 19, 2018 9:48 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Announces Completion of ProstaGene, LLC Acquisition

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its completion of the previously detailed acquisition of privately held ProstaGene, LLC. Per the update, Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and former chief executive officer of ProstaGene, has been appointed to the CytoDyn board of directors and named chief medical officer with responsibility for leading all PRO 140 (leronlimab) programs in non-HIV indications. “Richard is a driving force in CCR5 antagonist research and we gain significant expertise and intellectual property with this acquisition that advances the development of PRO 140 as a novel cancer metastasis therapeutic,” Anthony…

FridayNov 16, 2018 10:42 am

QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 HIV Monotherapy Trial Data Selected for Presentation at CROI 2019

Biotechnology company CytoDyn (OTCQB: CYDY) today announced that data from its ongoing investigative trial of PRO 140 (leronlimab) as a single subcutaneous therapy in HIV-1 infected patients was accepted for a poster presentation at next year’s Conference on Retroviruses and Opportunistic Infections (“CROI”). Vice President, Clinical Operations at Amarex Clinical Research Dr. Kush Dhody will present the abstract, “PRO 140 SC: Long-acting, Single-agent Maintenance Therapy for HIV-1 Infection,” at CROI 2019, to be held in Seattle March 4-7, 2019. “We are highly encouraged by the recently reported data from our monotherapy trial for patients receiving once-weekly injections of PRO 140…

TuesdayNov 13, 2018 10:16 am

QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 HIV Monotherapy Trial Shows Promising Results

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning provided an update on its PRO 140 (leronlimab) as a single agent for maintenance of HIV viral load suppression. Per the update, approximately 92 percent of newly enrolled patients administered PRO 140 in a 700 mg dosage as part of the CD03 Phase 3 investigative monotherapy trial have achieved viral load suppression. Patients enrolled in the Phase 3 monotherapy trial were prescreened for CCR5-tropic HIV-1 infection and treated for up to 12 weeks. “Our analysis of data indicate that patients treated with PRO 140 700 mg dose who achieve suppressed viral load…

FridayNov 09, 2018 12:07 pm

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) President and CEO Featured in Uptick Newswire’s Stock Day Podcast

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the featured interview of its President and CEO Nader Z. Pourhassan, Ph.D. with Stock Day's Everett Jolly. Jolly initiated the discussion by asking about CytoDyn’s PRO 140. The company’s flagship product is a humanized IgG4 monoclonal antibody that is designed to bind to cellular receptor CCR5, which plays various roles with implications in HIV, tumor metastasis and immune signaling. Pending FDA approval, which the company hopes to secure in Q4 2019, Pourhassan indicates that PRO 140 may be available to the public in 2020. "Most biotech companies, when they finish the biologic…

MondayNov 05, 2018 9:39 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Submits IND Application, Protocol for Phase 1b/2 Clinical Trial with PRO 140

CytoDyn (OTCQB: CYDY) this morning announced its submission of an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to carry out a phase 1b/2 clinical trial with PRO 140 as a therapy for metastatic triple-negative breast cancer. Currently, limited therapeutic options are available for triple-negative breast cancer due to an absence of standard biomarkers for targeted options. The original research and issued patents on CCR5 as a therapeutic target for cancer treatment were led by Richard Pestell, M.D., Ph.D., CytoDyn’s Interim Chief Medical Officer. Dr. Pestell’s published conclusions verified that CCR5 is a crucial receptor…

TuesdayOct 30, 2018 10:52 am

HIV Single Therapy PRO 140 Will Enable CytoDyn Inc. (CYDY) to “Take Off” Very Soon, President and CEO Says

Positive results in the PRO 140 clinical trials should mean good news for investors, CytoDyn President Nader Pourhassan said in an interview CytoDyn is currently undervalued but the effectiveness and practical appeal of PRO 140 should contribute to a turning point in stock prices PRO 140, a single agent therapy, is proving highly effective in the treatment of HIV; CytoDyn also planning an expansion of clinical trials to certain types of cancer The growth potential of CytoDyn Inc. (OTCQB: CYDY) is huge, company President and CEO Dr. Nader Pourhassan said in an interview with The Wall Street Transcript (http://ibn.fm/KWCIK). According to…

MondayOct 29, 2018 3:10 pm

QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) Innovative Anti-viral Agent Could Benefit the 36.9M Individuals Living with HIV

CytoDyn (OTCQB: CYDY), a biotechnology company, is focused on providing a treatment to the millions of people infected with the human immunodeficiency virus (HIV). A recent article discussing the company reads, “HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. During 2017, some 1.8 million people became newly infected with HIV, bringing the global total to 36.9 million people living with HIV, according to the World Health Organization (http://ibn.fm/udfzb). HIV continues to be a major public health issue, having claimed more than 35 million lives so far from every corner of…

FridayOct 26, 2018 10:06 am

CytoDyn Inc. (CYDY) to Complete Development of Prostate Cancer Prognostic Test Following Close of ProstaGene Acquisition

PCaTest has already proven a superior predictive ability in comparison with other genetic prognostic tests Cytodyn in the process of acquiring PCaTest developer ProstaGene and will launch a clinical study once the transaction is complete Prostate cancer is the second-most common type of cancer among American men, with almost 165,000 new cases expected this year Biotechnology company CytoDyn Inc. (OTCQB: CYDY) has unveiled a comprehensive strategy for the development of a genetic prostate cancer prognostic test (http://ibn.fm/GSEfb). Developed by ProstaGene, an entity that CytoDyn is in the process of acquiring, PCaTest has already demonstrated superior predictive ability in comparison to other…

Site Search

Company Search

Tag: CytoDyn Inc. CYDY